Reported 27 days ago
GSK has warned of a decrease in vaccine sales for 2024 following disappointing third-quarter performance for its RSV and shingles vaccines, leading to a drop in shares. The company now expects a low-single-digit percentage decline in vaccine sales, down from earlier growth projections. CEO Emma Walmsley highlighted recent challenges, including a narrowed age recommendation for RSV vaccines, but maintained confidence in the long-term prospects of its vaccines. GSK also recently reached a settlement to resolve lawsuits related to its Zantac heartburn drug.
Source: YAHOO